Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Endometrial Advancement After Rec or u-HCG Triggering

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by Universitair Ziekenhuis Brussel.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Merck Serono International SA
Information provided by:
Universitair Ziekenhuis Brussel
ClinicalTrials.gov Identifier:
NCT00953628
First received: August 5, 2009
Last updated: September 1, 2009
Last verified: September 2009

August 5, 2009
September 1, 2009
August 2005
December 2006   (final data collection date for primary outcome measure)
endometrium histology on the day of OPU [ Time Frame: day of oocytre pick up ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00953628 on ClinicalTrials.gov Archive Site
pregnancy rate [ Time Frame: 14 days after oocyte pick up ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Endometrial Advancement After Rec or u-HCG Triggering
Endometrial Advancement After Rec or u-HCG Triggering

The purpose of this study is to investigate any potential advantages of replacing human chorionic gonadotropin (uhCG) with recombinant human chorionic gonadotropin (recHCG) for final oocyte maturation with regard to Ovarian hyperstimulation syndrome (OHSS)pathophysiology, endometrium receptivity and embryo quality and clinical pregnancy.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Infertility
  • Drug: 10000 IU urinary HCG
    bolus 10000 units for ovulation triggering
  • Drug: 250 mcg recombinant HCG
    bolus 250 mcg for ovulation triggering in IVF patients
  • Active Comparator: o Group A=uHCG for triggering ovulation
    Intervention: Drug: 10000 IU urinary HCG
  • Experimental: o Group B=recHCG for triggering ovulation
    Intervention: Drug: 250 mcg recombinant HCG
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
130
December 2008
December 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Less than 36 years old
  • Male or tubal infertility
  • FSH<12 on day 3

Exclusion Criteria:

  • Endometriosis stage 3 & 4
Female
20 Years to 36 Years
No
Contact information is only displayed when the study is recruiting subjects
Belgium
 
NCT00953628
recHCG001
No
Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel
Universitair Ziekenhuis Brussel
Merck Serono International SA
Study Director: Paul Devroey, Professor Professor or OB-GYN
Universitair Ziekenhuis Brussel
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP